Johnson & Johnson

JNJ Healthcare Drug Manufacturers - General NYSE

Back to Search

$227.87

$-2.79 (-1.21%)

Open: $229.03 | High: $229.99 | Low: $227.02 | Prev Close: Prev Close: $230.65

Market Cap: $549.13B

Volume: 2.0M | Avg: 8.4M

Last updated: April 24, 2026 at 04:02 PM
Investment Rating
B+

Neutral

Overall Score: 60/100

Rating Breakdown:
DCF Score 4/5
80%
Buy
ROE Score 5/5
100%
Strong Buy
ROA Score 5/5
100%
Strong Buy
D/E Score 1/5
20%
Strong Sell
P/E Score 2/5
40%
Sell
P/B Score 1/5
20%
Strong Sell
Add to Watchlist Add to Portfolio
Stock Score Analysis
D

Stock Score: 562

Comprehensive Quality Assessment

Component Breakdown:
Efficiency 45
Financial Health 85
Growth 20
Market Sentiment 10
Risk 50
Lower is better
Valuation 12
Momentum 40
View Full Stock Score Dashboard
Valuation Metrics
Valuation Ratios
P/E Ratio 20.64
P/B Ratio 6.86
P/S Ratio 5.70
EPS $11.04
Beta 0.33
Shares Outstanding 2.41B
Price Range & Moving Averages
52-Week High $251.71
52-Week Low $146.12
SMA 50 $240.49
SMA 200 $204.19
Dividend Information
Dividend Yield 2.28%
Annual Dividend $5.20
Earnings
Next Earnings July 15, 2026 04:00 AM ET
Financial Ratios
Margins
Gross Margin 69.1%
Operating Margin 26.9%
Net Margin 21.8%
Returns
ROE 26.3%
ROA 10.5%
Liquidity & Leverage
Debt/Equity 0.22
Current Ratio 1.03
Quick Ratio 0.77
Balance Sheet
Total Assets $199.21B
Total Liabilities $117.67B
Total Equity $81.54B
Cash $19.71B
Total Debt $47.93B
Net Debt $28.22B
Income Statement
Revenue $94.19B
Gross Profit $68.56B
Operating Income $25.60B
Net Income $26.80B
EBITDA $41.05B
Revenue/Share $39.41
Cash Flow
Operating CF $24.53B
CapEx $4.83B
Free Cash Flow $19.70B
Book Value/Share $33.20
Tangible Book/Share $-6.72
Equity/Share $33.20
Technical Indicators
RSI (14) 30.52 Neutral
MACD
-3.14 Signal: -1.71
Volatility 18.64%
Trading Signal Bearish
Performance & Returns
Total Returns
1 Year +45.81%
Risk-Adjusted Returns
Sharpe Ratio 2.48 Excellent
Volatility (Ann.) 17.72% Low Risk
vs S&P 500 (SPY)
JNJ (1Y) +45.81%
S&P 500 (1Y) +14.41%
Alpha (Excess Return) +31.4%
Risk-free rate: 4.5% (3-month US Treasury) • Based on 199 trading days
Sector Comparison (Healthcare)
Compared to 49 peers in Healthcare
Metric JNJ Sector Avg Percentile
P/E Ratio 20.64 26.35 30%
P/B Ratio 6.86 -21.16 78%
ROE (%) 26.26% -10.43% 76%
Net Margin (%) 21.83% 9.19% 80%
Stock Score 562 548.0 50%
1Y Return (%) +45.81 % +4.29 % 96%
Percentile: 0% = worst in sector, 100% = best in sector
📊 Historical Price Analysis (Last 200 Days)

Loading chart...

Technical Analysis
Ticker Close SMA 5 SMA 8 SMA 13 SMA 50 SMA 200 RSI (14) MACD Volatility (%) Volume Signal SMA Decision
JNJ $227.87 $228.08 $231.34 $234.48 $240.28 $204.54 30.52 -3.14 18.64% 530874 Neutral Bearish Stack
Candlestick Patterns

There wasn't any recognizable pattern for the JNJ stock

News Sentiment
Ticker Headline Sentiment Source URL
JNJ Gentry Private Wealth LLC Acquires Shares of 2,284 Johnson & Johnson $JNJ Neutral defenseworld.net Read More
JNJ Johnson & Johnson $JNJ Shares Purchased by Evergreen Capital Management LLC Neutral defenseworld.net Read More
JNJ Johnson & Johnson to launch on TrumpRx with four of its prescription drugs, CBS News reports Neutral reuters.com Read More
JNJ The FDVV ETF Delivers Higher 5-Year Growth Than the HDV ETF Positive fool.com Read More
JNJ A $900,000 Stock Portfolio Exposed to Just Three Sectors Is a Retirement Time Bomb Neutral 247wallst.com Read More
Recent Insider Trading

No recent insider trading data available for JNJ

Company Information

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

CEO Joaquin Duato
Employees 138100
Country US
IPO Date 1943-01-02
Exchange NYSE
Website https://www.jnj.com
Sector Healthcare
Industry Drug Manufacturers - General
Similar Stocks (Healthcare - Drug Manufacturers - General)
LLY

Eli Lilly and Company

Price: $917.23
Change: -0.46%
Market Cap: $8666B
P/E: 39.98
Score: C (617)
View Details
ABBV

AbbVie Inc.

Price: $198.65
Change: -1.14%
Market Cap: $3513B
P/E: 83.47
Score: E (447)
View Details
MRK

Merck & Co., Inc.

Price: $111.88
Change: -2.39%
Market Cap: $2766B
P/E: 15.37
Score: C (635)
View Details
AMGN

Amgen Inc.

Price: $347.74
Change: -0.14%
Market Cap: $1874B
P/E: 24.42
Score: D (587)
View Details
Rating Metrics Explained
DCF Score (Discounted Cash Flow)

Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.

ROE Score (Return on Equity)

Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.

ROA Score (Return on Assets)

Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.

D/E Score (Debt-to-Equity)

Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.

P/E Score (Price-to-Earnings)

Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.

P/B Score (Price-to-Book)

Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.

Rating Recommendations:

Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:

  • Strong Buy (5/5): Excellent score - strong positive indicator
    • The metric significantly outperforms industry averages (top 20% of companies)
    • Indicates exceptional financial health or attractive valuation in that category
  • Buy (4/5): Good score - positive indicator
    • Above-average performance (top 40% of companies)
    • Shows strong fundamentals with room for improvement
  • Neutral (3/5): Average score - neutral indicator
    • Performance in line with industry median (middle 20%)
    • Neither significantly positive nor negative signal
  • Sell (2/5): Below average - negative indicator
    • Below-average performance (bottom 40% of companies)
    • Suggests weakness in this particular metric
  • Strong Sell (1/5): Poor score - strong negative indicator
    • Significantly underperforms industry (bottom 20%)
    • Indicates potential risk or overvaluation in that category
Note: The overall rating combines all six component scores to provide a comprehensive investment assessment. No single metric should be used in isolation for investment decisions.